A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the ...
Learn more Novartis has netted a pair of regulatory wins, winning European approval for an oral therapy in chronic ...
For many patients without a primary care provider, a dermatologist may be the only healthcare professional who can counsel ...
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1Rhapsido recommended in 2026 International Urti ...
CSU affects nearly 4 million people in Europe; more than 50% continue to experience debilitating symptoms after conventional antihistamine therapy 3-5 Basel, April 27, 2026 – Novartis announced today ...
We all know the standard anti-aging lectures. Smoking causes wrinkles, speeds up collagen breakdown, and generally ruins your ...
Insmed's updated fair value estimate has shifted slightly, from US$214.32 to US$212.50 per share, putting fresh attention on how analysts are recalibrating their views. Recent reports around Brinsupri ...
They were symptoms of hidradenitis suppurativa, a chronic inflammatory skin condition characterized by recurring abscesses, ...
HKeybio launches world's first NHP HS model with high clinical consistency to tackle global drug R&D bottleneck: Watertown, Massachusetts Thursday, April 23, 2026, 14:00 Hrs [IST] ...
Children with hidradenitis suppurativa often receive antibiotics for about a year before switching to other therapies, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results